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STUDY QUESTION: Do genome-wide association study (GWAS) data for endometriosis provide insight into novel biological pathways
associated with its pathogenesis?
SUMMARY ANSWER: GWAS analysis uncovered multiple pathways that are statistically enriched for genetic association signals, analysis
of Stage A disease highlighted a novel variant in MAP3K4, while top pathways signiﬁcantly associated with all endometriosis and Stage A dis-
ease included several mitogen-activated protein kinase (MAPK)-related pathways.
WHAT IS KNOWN ALREADY: Endometriosis is a complex disease with an estimated heritability of 50%. To date, GWAS revealed 10
genomic regions associated with endometriosis, explaining <4% of heritability, while half of the heritability is estimated to be due to common
risk variants. Pathway analyses combine the evidence of single variants into gene-based measures, leveraging the aggregate effect of variants in
genes and uncovering biological pathways involved in disease pathogenesis.
STUDY DESIGN, SIZE, DURATION: Pathway analysis was conducted utilizing the International Endogene Consortium GWAS data,
comprising 3194 surgically conﬁrmed endometriosis cases and 7060 controls of European ancestry with genotype data imputed up to 1000
Genomes Phase three reference panel. GWAS was performed for all endometriosis cases and for Stage A (revised American Fertility Society
(rAFS) I/II, n = 1686) and B (rAFS III/IV, n = 1364) cases separately. The identiﬁed signiﬁcant pathways were compared with pathways previ-
ously investigated in the literature through candidate association studies.
PARTICIPANTS/MATERIALS, SETTING, METHODS: The most comprehensive biological pathway databases, MSigDB (including
BioCarta, KEGG, PID, SA, SIG, ST and GO) and PANTHER were utilized to test for enrichment of genetic variants associated with endomet-
riosis. Statistical enrichment analysis was performed using the MAGENTA (Meta-Analysis Gene-set Enrichment of variaNT Associations)
software.
MAIN RESULTS AND THE ROLE OF CHANCE: The ﬁrst genome-wide association analysis for Stage A endometriosis revealed a
novel locus, rs144240142 (P = 6.45 × 10−8, OR = 1.71, 95% CI = 1.23–2.37), an intronic single-nucleotide polymorphism (SNP) within
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MAP3K4. This SNP was not associated with Stage B disease (P = 0.086). MAP3K4 was also shown to be differentially expressed in eutopic
endometrium between Stage A endometriosis cases and controls (P = 3.8 × 10−4), but not with Stage B disease (P = 0.26). A total of 14 path-
ways enriched with genetic endometriosis associations were identiﬁed (false discovery rate (FDR)-P < 0.05). The pathways associated with
any endometriosis were Grb2-Sos provides linkage to MAPK signaling for integrins pathway (P = 2.8 × 10−5, FDR-P = 3.0 × 10−3), Wnt signaling
(P = 0.026, FDR-P = 0.026) and p130Cas linkage to MAPK signaling for integrins pathway (P = 6.0 × 10−4, FDR-P = 0.029); with Stage A endo-
metriosis: extracellular signal-regulated kinase (ERK)1 ERK2 MAPK (P = 5.0 × 10−4, FDR-P = 5.0 × 10−4) and with Stage B endometriosis: two
overlapping pathways that related to extracellular matrix biology—Core matrisome (P = 1.4 × 10−3, FDR-P = 0.013) and ECM glycoproteins
(P = 1.8 × 10−3, FDR-P = 7.1 × 10−3). Genes arising from endometriosis candidate gene studies performed to date were enriched for
Interleukin signaling pathway (P = 2.3 × 10−12), Apoptosis signaling pathway (P = 9.7 × 10−9) and Gonadotropin releasing hormone receptor pathway
(P = 1.2 × 10−6); however, these pathways did not feature in the results based on GWAS data.
LARGE SCALE DATA: Not applicable.
LIMITATIONS, REASONS FOR CAUTION: The analysis is restricted to (i) variants in/near genes that can be assigned to pathways,
excluding intergenic variants; (ii) the gene-based pathway deﬁnition as registered in the databases; (iii) women of European ancestry.
WIDER IMPLICATIONS OF THE FINDINGS: The top ranked pathways associated with overall and Stage A endometriosis in particular
involve integrin-mediated MAPK activation and intracellular ERK/MAPK acting downstream in the MAPK cascade, both acting in the control of
cell division, gene expression, cell movement and survival. Other top enriched pathways in Stage B disease include ECM glycoprotein pathways
important for extracellular structure and biochemical support. The results highlight the need for increased efforts to understand the functional
role of these pathways in endometriosis pathogenesis, including the investigation of the biological effects of the genetic variants on down-
stream molecular processes in tissue relevant to endometriosis. Additionally, our results offer further support for the hypothesis of at least
partially distinct causal pathophysiology for minimal/mild (rAFS I/II) vs. moderate/severe (rAFS III/IV) endometriosis.
STUDY FUNDING/COMPETING INTEREST(S): The genome-wide association data and Wellcome Trust Case Control Consortium
(WTCCC) were generated through funding from the Wellcome Trust (WT084766/Z/08/Z, 076113 and 085475) and the National Health
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Introduction
Endometriosis is a chronic inﬂammatory disease in which endometrial-
like tissue is located outside the uterus. It is associated with debilitating
pelvic pain and reduced fertility, and affects 1.5 M women in the UK
(176 M worldwide) (Simoens et al., 2012). Treatments are limited to
surgical removal of disease tissue, and hormonal drugs with many side
effects. Identifying novel diagnostic tools and treatments requires a bet-
ter understanding of the pathogenesis of endometriosis. Although
advances have certainly been made in the past decade in understanding
of biological processes likely to promote the maintenance and growth of
lesions, the actual causes remain largely unclear. Previous investigations
have considered the potential roles of steroids, endometrial aberrations,
altered peritoneal environment, reduced immune surveillance and
increased angiogenic capacity in the pathogenesis (Giudice and Kao,
2004) but, crucially, it is not known whether these processes are a
necessary cause, or rather an effect of the disease process.
One method to improve understanding of complex disease causality
is through the identiﬁcation of genetic factors underlying disease risk,
through genome-wide association studies (GWAS). The involvement
of genetic factors in the development of endometriosis is supported by
numerous studies (Simpson, et al., 1980; Bischoff and Simpson, 2004;
Rahmioglu et al., 2015a, 2015b), and its heritability is estimated at
~50% (Treloar et al., 1999; Saha et al., 2015). Before the advent of
GWAS, candidate gene association studies were the most common
type of study in the investigation of genetic factors underlying complex
diseases, and many such studies have been published for endometri-
osis (Rahmioglu, et al., 2012; Montgomery et al., 2014). Results from
candidate association studies have been poorly replicated for a num-
ber of reasons that are intrinsic to their design (Rahmioglu et al.,
2015b). GWAS bypasses the weaknesses of candidate association
studies as they are not based on an a priori biological hypothesis.
The GWAS for endometriosis conducted to date have identiﬁed 10
genome-wide signiﬁcantly associated variants (Rahmioglu et al., 2014;
Zondervan et al., 2016), in data sets including women of European and
Japanese ancestry (Uno et al., 2010; Painter et al., 2011; Nyholt et al.,
2012; Albertsen et al., 2013; Sapkota et al., 2015). Most of these show
stronger association with moderate/severe disease, but together they
explain <4% of heritability (Rahmioglu et al., 2014; Zondervan et al.,
2016). Of the total variance in disease risk, 24% has been estimated to
be due to common genetic variants (Lee et al., 2013). Larger GWAS
meta-analyses are required to bring the ﬁeld of endometriosis up to
speed with progress made in other areas (e.g. breast cancer: 67 com-
mon genetic predisposing loci are now known, from meta-analysis of
>55 000 cases; Michailidou et al., 2013); however, other approaches
are also needed to identify remaining genetic variants and pathways.
One disadvantage of GWAS is the requirement for a very stringent
genome-wide signiﬁcance threshold (P < 5 × 10−8) to identify var-
iants likely to be genuinely associated with a complex disease. Such a
stringent threshold is necessary because of the large number of
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statistical tests being conducted when testing each individual variant
for association with the disease; however, it results in true associa-
tions not reaching this threshold being missed. One approach to
uncover genetic variants associated with the disease under this
multiple-testing burden is to aggregate genetic variants passing a pre-
deﬁned signiﬁcance threshold for association with a disease into
gene-based measures and to investigate whether the number of asso-
ciated genes in a given pathway is greater than expected by chance
(Perry et al., 2009).
We aimed to explore whether the largest GWAS data set to date
comprising 3194 surgically conﬁrmed endometriosis cases (Painter
et al., 2011) can provide insight into novel biological pathways causally
involved in endometriosis pathogenesis. We tested pathways, without
any preselection, for evidence of enrichment of genetic variants asso-
ciated with endometriosis. We also performed the ﬁrst GWAS ana-
lysis for minimal/mild (Stage A) endometriosis. Lastly, we investigated
to what extent pathways that have been investigated most frequently
through candidate gene association studies feature in those highlighted
in GWAS-based pathway analyses.
Materials andMethods
GWAS participants and phenotyping
The International Endogene Consortium (IEC) GWAS data included 3194
surgically conﬁrmed endometriosis cases, and 7060 controls of European
ancestry from Australia and the UK (Supplementary Table SI) (Painter
et al., 2011). Cases were classiﬁed according to the revised American
Fertility Society (rAFS) classiﬁcation for endometriosis severity through
assessment of surgical records and grouped into two sub-phenotypes:
Stage A (rAFS Stage I or II, or some ovarian disease with a few adhesions:
peritoneal or superﬁcial ovarian disease with ﬁlmy adhesions, n = 1686)
and Stage B (rAFS Stage III–IV: deep ovarian and/or rectovaginal disease
with dense adhesions, n = 1364) (ASRM, 1985). Australian controls
included 1870 parents and siblings of adolescent twins recruited as part of
the Brisbane Adolescent Twin Study. The UK controls included 3000 indi-
viduals from the 1958 British Birth Cohort and 3000 from National
Blood Service Donors, provided by the Wellcome Trust Case Control
Consortium 2 (Wellcome Trust Case Control et al., 2007, 2010).
Genotyping and imputation
Cases were genotyped using the Illumina Human670Quad BeadArray, the
Australian controls on Illumina Human610Quad and the UK controls on
Illumina Human1M-Duo. The genotype data, including the autosomes and
chromosome X, were imputed to the latest 1000 Genomes Phase three
reference panel (October 2014). Pre-phasing and imputation were per-
formed using SHAPEIT2 (Delaneau et al., 2014) and IMPUTE2 (Howie
et al., 2009) softwares, respectively.
Genome-wide association and functional
analyses
Three sets of genome-wide association analysis were performed: (i) All
cases (n = 3194), (ii) Stage A cases (n = 1686) and (iii) Stage B cases
(n = 1364) vs. controls (n = 7060) to see whether the two sub-phenotypes
share similar underlying or have distinct underlying genetic factors in their
causation. Logistic regression analysis including a covariate representing the
Australian and the UK strata was performed in SNPTESTv2 (Marchini et al.,
2007). After genome-wide association analysis, the results from biallelic
single-nucleotide polymorphisms/(INsertion/DELetion) (SNPs/INDELs)
with imputation quality >0.8 and minor allele frequency (MAF) >0.01 were
retained (n = 8 943 157). QQ plots for all cases, Stage A and Stage B dis-
ease associations are provided in Supplementary Figure S1.
Genetic variants associated with overall, Stage A and Stage B disease
(P < 1 × 10−6) were checked for functional evidence in the genomic region
in the Encyclopedia of DNA Elements (ENCODE) consortium data
(Consortium, 2012). Histone modiﬁcation marks were identiﬁed from
seven cell lines (GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK,
NHLF) and DNAse I hypersensitivity peaks identiﬁed from 95 cell types
from ENCODE database using UCSC (University of California, Santa
Cruz) genome browser annotation tools (endometrial tissue limited to
four samples only).
The genes closest to the genetic variants associated with overall, Stage
A and Stage B disease (P < 1 × 10−6) were tested for differential expres-
sion using a previously published, publicly available data set (GEO
Accession: GSE51981) of eutopic endometrium from 77 endometriosis
cases (Stage A n = 27, Stage B n = 48, unclassiﬁed n = 2) and 71
endometriosis-free controls assayed using the Affymetrix Human Genome
U133 Plus 2.0 Array (Tamaresis et al., 2014). Comparisons between
groups to identify differentially expressed genes were conducted on ori-
ginal submitter-supplied processed data using GEOquery and limma R
packages in GEO2R (Smyth, 2005; Davis and Meltzer, 2007). We per-
formed differential expression analysis including all cases vs. controls from
all menstrual phases, checked whether the most signiﬁcant probes per
gene region were differentially expressed between menstrual phases, and
if so, conducted within-phase differential expression analysis between
cases and controls.
Pathway analysis using GWAS results
in MAGENTA
Pathway genetic enrichment analysis was performed for (i) all endometri-
osis, (ii) Stage A endometriosis, (iii) Stage B endometriosis GWAS results,
using MAGENTA (Meta-Analysis Gene-set Enrichment of variaNT
Associations) software (Segre et al., 2010) (Supplementary Figure S2).
MAGENTA ﬁrst maps SNPs to genes taking 110 Kb upstream and 40 Kb
downstream of each gene as extended boundaries to include regulatory
regions. Each gene is then assigned a genetic score (GS), which is the
P-value of the most signiﬁcant SNP within the gene’s extended boundaries,
corrected for six potential confounding factors of physical and genetic
properties of genes through a step-wise multiple linear regression: (i) the
physical size of the gene, (ii) number of SNPs per kilobase for each gene,
(iii) estimated number of independent SNPs per gene, (iv) number of
recombination hotspots spanning each gene, (v) genetic distance of the
gene and (vi) linkage disequilibrium (LD) unit distance per gene.
We built a pathway database library from the two most comprehen-
sive and up-to-date resources, Molecular Signatures database v5.1
(MSigDB) and PANTHER pathway database v10.0 (15 December
2015), and used this library in the pathway genetic enrichment analyses
(Supplementary Figure S2). The Molecular Signatures Database (MSigDB)
version 5.1 (Mootha et al., 2003; Subramanian et al., 2005) (http://
software.broadinstitute.org/gsea/msigdb/index.jsp) is the most exten-
sive resource of gene sets/pathways, currently comprising 13 311 non-
independent gene sets. From this database, we downloaded (i) the
curated canonical pathways (C2-CP), which include 1330 gene sets amal-
gamated from BioCarta, Kyoto Encyclopedia of Genes and Genomes
(KEGG), Matrisome, Pathway Interaction Database (PID), Reactome,
SigmaAldrich (SA), Signaling Gateway (SIG), Signaling Transduction KE
(ST) and SuperArray and (ii) Gene Ontology (GO) gene sets, which
include 1454 gene sets comprised of biological processes, cellular com-
ponents, molecular functions. We also downloaded 149 curated canon-
ical pathways from the PANTHER database version 10.0 (Mi et al.,
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2016), which were not part of the MSigDB. The total number of path-
ways included was 2933, with the effective number tested n = 2860
(excluding pathways with <10 genes) (Supplementary Figure S2).
MAGENTA employs a Gene Set Enrichment Analysis (GSEA)-like statis-
tic (Mootha et al., 2003; Subramanian et al., 2005) to the gene association
P-values adjusted for confounding factors. The null hypothesis in the ana-
lysis is that the tested genes are randomly distributed in terms of signiﬁ-
cance (P-values) of association with the disease of interest, within each
pathway. The alternative hypothesis assumes enrichment above a given
rank cutoff compared with multiple random gene sets. The rank cutoff is a
pre-determined gene P-value cutoff, and is deﬁned as a given percentile of
all gene P-values in the genome. We used a 95% cutoff threshold for signiﬁ-
cance. Multiple-testing correction was applied through calculation of the
false discovery rate (FDR) for resources with >25 genesets/pathways.
Results from smaller resources with <25 pathways, which were more
likely to be independent of each other, were also adjusted using a
Bonferroni correction (P = 0.05/number of pathways tested). The soft-
ware was obtained from http://www.broadinstitute.org/mpg/magenta/
and ran locally in MATLAB R2013a.
Identiﬁcation of pathways suggested by
previously published candidate gene studies
The 122 candidate genes (Rahmioglu et al., 2012) that have been investi-
gated for association with endometriosis were queried using the
PANTHER 10.0 database on 15 December 2015, which contains pathway
information on 20 000 genes within 149 curated human pathways. The
genes were tested for over-representation in these pathways (Mi et al.,
2016) by calculating the difference between the observed fraction of genes
in that pathway and the number expected by chance, with signiﬁcance of
over-representation tested using a Fisher’s exact test. The PANTHER
pathways that showed statistically signiﬁcant (P < 0.05 after Bonferroni
multiple-testing correction) over-representation of the candidate genes
were deﬁned as the pathways that have been investigated indirectly
through candidate gene association studies (Supplementary Figure S2).
Results
After imputation to the latest 1000 Genomes Phase three reference
panel, no novel genome-wide signiﬁcant associations with overall
endometriosis (n = 3194) or Stage B (n = 1364) (Table I,
Supplementary Figure S3) were observed; the well-established
rs12700667 remained the strongest association (OR = 1.32, 95% CI
1.20–1.46; P = 2.45 × 10−9 with Stage B disease). The second
genome-wide signiﬁcant locus remained at FN1, though imputation
altered the strongest associated SNP from the previously reported
rs1250258 (Painter et al., 2011) to highly correlated (r2 = 0.96)
rs1250248 (OR = 0.81, 95% CI 0.74–0.88; P = 3.48 × 10−8). We
found 11 loci (Table I) showing nominal association (P < 1.0 × 10−6),
3 of which were established endometriosis loci (WNT4, CDKN2BAS1,
ID4) and 8 had not previously been reported. Of these eight loci,
three were associated with all endometriosis (LAMC3, CAPN14 and
DEFA1), and six with Stage B disease (NAALADL2, NR2C1, C14orf132,
FOXP2, CDH20 and LAMC3).
Our ﬁrst ever GWAS analysis for Stage A endometriosis (n = 1686
cases) revealed a novel locus, rs144240142 (P = 6.45 × 10−8, OR
1.71, 95%CI 1.23–2.37), an intronic SNP with MAF of 0.01, imputation
info score >0.8, within the MAP3K4 gene (Table I, Fig. 1). In addition,
four more loci were associated with Stage A disease with nominal sig-
niﬁcance (P < 1.0 × 10−6): two INDELS within CDC73 and CSMD1
genes, and two intergenic SNPs near EMX2 and ALCAM genes
(Table I).
For each of the loci, we explored potential functionality using
ENCODE (the Encyclopedia Of DNA Elements) Project data
(Consortium, 2012) (see Materials and Methods). These showed most
endometriosis-associated SNPs to be located near elements of the
genome that are designated to be regulatory in a variety of cell types
(Table I). The cell lines in which the regulatory elements were
found included GM12878 (lymphoblastoid cell line), H1-hESC (human
embryonic stem cells), HSMM (human skeletal muscle myoblasts),
HUVEC (human umbilical vein endothelial cells), K562 (immortalized
cell line produced from a female patient with chronic myelogenous leu-
kemia), NHEK (normal human epidermal keratinocytes) and NHLF
(normal human lung ﬁbroblasts) (Consortium, 2012). The strongest
associated endometriosis locus, rs12700667 (P = 2.45 × 10−9), is
located in known epigenetic regulators (histone modiﬁcation marks
H3K27ac, H3K4Me1 and H3K4Me3), in/near transcription factor
binding (TFB) sites for a number of genes, and near a microRNA
(miR148a, 87.9 Kb away); the nearest gene is NFE2L3 (Nuclear Factor,
Erythroid 2-Like 3), located 290.2 Kb away (Table I). MAP3K4 is tran-
scribed in all seven cell lines (ENCODE RNA sequencing data) while
rs144240142 is located near (±1 kb) TFB sites for EGR1, CEBPB,
FOSL1 and FOS.
We performed differential expression analysis for each of the gen-
etic loci, using the largest publicly available eutopic endometrium
microarray expression data set (Tamaresis et al., 2014) (see Materials
and Methods). Differential expression between 77 cases vs. 71 con-
trols was observed for ID4, NFE2L3, MAP3K4, CDC73, CSMD1, FN1,
NR2C1 and C14orf132 (FDR-corrected P < 0.05). Of these, ID4,
NFE2L3 and MAP3K4 were also differentially expressed between pro-
liferative, early and mid secretory phases. Differential expression ana-
lysis within each phase for these loci showed that ID4 and MAP3K4
were signiﬁcantly differentially expressed between cases and controls
in the proliferative phase, while NFE2L3 was not differentially ex-
pressed between cases and controls in any phase. All the loci asso-
ciated with Stage A disease in our GWAS (MAP3K4, CDC73, EMX2,
ALCAM) were more strongly differentially expressed when the analysis
of the expression data set was restricted to Stage I/II cases vs. controls
(27 cases vs. 71 controls). For Stage B associated loci, FN1, NR2C1,
C14orf132, NFE2L3, we similarly observed stronger evidence of differ-
ential expression when analysis was restricted to Stage III/IV cases vs.
controls (48 cases vs. 71 controls) (Supplementary Table SII).
Table II shows the results of the pathways that were signiﬁcantly
over-represented (‘enriched’) in the GWAS results, after correction
for multiple testing (number of pathways; FDR-P < 0.05 or Bonferroni-
P < 0.05 (see Materials and Methods)).WNT signaling—a key pathway
implicated in our previous GWAS and pathway analyses—was signiﬁ-
cantly associated with all endometriosis at FDR < 0.05 but not after
stringent Bonferroni correction taking account of the number of path-
ways in the SA database (see Materials and Methods). The top path-
ways signiﬁcantly associated with all and Stage A endometriosis were
mitogen-activated protein kinases (MAPK)-related, and originated
from the large REACTOME database (Table II). Grb2-Sos provides link-
age to MAPK signaling for integrins (all endometriosis, enrichment
P = 2.8 × 10−5, FDR-P = 3.0 × 10−3) is a pathway that includes 15
genes, involving integrin clustering by ﬁbronectin stimulation, linked to
extracellular signal-regulated kinase (ERK)2 MAPK signaling. The genes
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Table I Independent signals from overall, Stage A and Stage B GWAS results with P < 1 × 10−6.
Rsid (Chr:
Position)
A1/A2 (MAF) Overall P Overall OR
(95% CI)
Stage A P Stage A OR
(95% CI)
Stage B P Stage B OR
(95% CI)
Variant type Nearest gene
(distance)
Regulatory function from
ENCODE (±25 Kb)*
Overall endometriosis GWAS
rs6908034
(6:19773930)
G/A (0.16) 5.36 × 10−7 1.22 (1.12–1.32) 0.012 1.13 (1.02–1.25) 7.31 × 10−7 1.30 (1.17–1.45) Intronic SNP ID4 (64 056bp) Located in an anti-sense
RNA, RP1-167F1.2
rs12700667
(7:25901639)
G/A (0.25) 5.57 × 10−7 1.17 (1.09–1.25) 0.038 1.07 (0.98–1.16) 2.45 × 10−9 1.32 (1.20–1.46) Intergenic SNP NFE2L3
(290 221bp)
(1) Near a microRNA,
mir148a (87 900bp), (2) In
histone modiﬁcation marks
H3K27AC, H3K4Me1,
H3K4Me3, (3) In/near TFB
sites for MXI1, POLR2A,
TBP, NFYA, ARID3A,
GATA3, ELF1, TEAD4,
JUND, SMARCA4, SIX5,
MAX, NRF1, RFX5, CHD2,
CREB1, CEBPC, ATF1,
KDM5B, JUN, NFYB,
RUNX3, SP4, MAZ, SIN3A,
ZBTB7A, MYC, STAT3,
HMGN3, CCNT2, CBX3,
TCF3, BHLHE40, EP300,
E2F6, FOXP2, GABPA,
ZNF143, SPI1, USF1, EGR1,
E2F4, E2F1, MAFK, TCF7L2,
POU2F2, TAF1, PHF8, IRF1,
FOXA1 (±1 Kb)
rs55938609
(1:22470451)
G/C (0.16) 6.11 × 10−7 1.24 (1.15–1.35) 2.36 × 10−3 1.17 (1.06–1.29) 8.33 × 10−7 1.33 (1.20–1.48) SNP Upstream
of gene
WNT4 (932bp) (1) In histone modiﬁcation
mark H3K4Me1, (2) In/near
TFB sites for EZH2, FOXA2,
FOXA1, EZH2, RAD21,
CTCF, PAX5, POLR2A,
E2F1, EGR1, CCNT2,
SIN3A, RBBP5 (±1 Kb)
rs138913144
(9:133897939)
A/ATATT (0.07) 6.38 × 10−7 0.77 (0.69–0.87) 4.47 × 10−3 0.86 (0.74–1.00) 9.94 × 10−7 0.68 (0.57–0.81) Intronic
Insertion
LAMC3 (0bp) (1) Near a small nucleolar
RNA, SNORA31 (1246bp),
(2) Near histone
modiﬁcation mark H3K4Me1
rs116175374
(2:31425185)
G/A (0.04) 6.45 × 10−7 0.69 (0.59–0.81) 4.03 × 10−5 0.68 (0.55–0.85) 1.79 × 10−3 0.73 (0.58–0.92) Intronic SNP CAPN14 (0bp) (1) Near histone
modiﬁcation mark H3K4Me1
rs60966186
(8:6831204)
A/G (0.19) 9.85 × 10−7 0.85 (0.79–0.92) 6.71 × 10−5 0.87 (0.79–0.96) 3.62 × 10−5 0.84 (0.75–0.93) Intergenic SNP DEFA1 (4088bp) (1) Near histone
modiﬁcation mark
H3K4Me1, (2) Near TFB site
for KAP1 (±1 Kb)
Stage A endometriosis GWAS
T/C (0.01) 5.79 × 10−5 1.46 (1.10–1.93) 6.45 × 10−8 1.71 (1.23–2.37) 0.086 1.19 (0.79–1.78) Intronic SNP MAP3K4 (0bp)
784
U
im
arietal.
rs144240142
(6:161503024)
(1) Transcribed on seven cell
lines assayed by RNA-seq
data, (2) Near TFB sites for
EGR1, CEBPB, FOSL1, FOS
(±1 Kb)
rs200922190
(1:193203491)
A/AAATTAT
(0.22)
2.35 × 10−4 0.90 (0.84–0.97) 1.79 × 10−7 0.83 (0.75–0.91) 0.097 0.97 (0.88–1.07) Intronic
Insertion
CDC73 (0bp) (1) Transcribed on seven cell
lines assayed by RNA-seq
data, (2) Near TFB sites for
TCF7L2, SETDB1, FOXA1,
KAP1, TFAP2A, TFAP2C,
FOS, ELF1, FAM48A
(±1 Kb). (3) Near histone
modiﬁcation mark
H3K4Me1, H3K27Ac
8:2806920 G/
GAAAGAAAAG
AAAAGAAAAG
(0.17)
0.73 1.36 (0.43–4.30) 3.82 × 10−7 0.79 (0.71–0.88) 0.14 0.94 (0.84–1.05) Intronic
deletion
CSMD1 (0bp) (1) Near histone
modiﬁcation mark
H3K4Me1, (2) Near TFB
sites for MAX, FOXP2,
REST.
rs855965
(10:119443759)
G/A (0.34) 1.23 × 10−3 0.89 (0.84–0.95) 4.10 × 10−7 0.81 (0.74–0.88) 0.96 1.00 (0.92–1.09) Intergenic SNP EMX2
(1 34 702bp)
(1) Near histone
modiﬁcation mark
H3K4Me1, (2) Near TFB
sites for STAT3, CTCF,
RAD21, SMC3, ESR1
rs113850637
(3:103850400)
C/T (0.16) 4.56 × 10−4 1.15 (1.06–1.25) 8.08 × 10−7 1.28 (1.16–1.41) 0.60 1.01 (0.90–1.13) Intergenic SNP ALCAM
(1 235 853bp)
(1) Near a microRNA,
mir548a3 (53076), (2) Near
histone modiﬁcation mark
H3K4Me1, (3) Near TFB
sites for EP300, GATA2,
JUN, FOS, MAX, USF1, YY1,
CTCF, TCF12, POU5F1
Stage B endometriosis GWAS
rs12700667
(7:25901639)
G/A (0.25) 5.57 × 10−7 1.17 (1.09–1.25) 0.038 1.07 (0.98–1.16) 2.45 × 10−9 1.32 (1.20–1.46) Intergenic SNP NFE2L3
(290 221bp)
(1) Near a microRNA,
mir148a (87900 bp), (2) In
histone modiﬁcation marks
H3K27AC, H3K4Me1,
H3K4Me3, (3) In/near TFB
sites for MXI1, POLR2A,
TBP, NFYA, ARID3A,
GATA3, ELF1, TEAD4,
JUND, SMARCA4, SIX5,
MAX, NRF1, RFX5, CHD2,
CREB1, CEBPC, ATF1,
KDM5B, JUN, NFYB,
RUNX3, SP4, MAZ, SIN3A,
ZBTB7A, MYC, STAT3,
HMGN3, CCNT2, CBX3,
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Table I Continued
Rsid (Chr:
Position)
A1/A2 (MAF) Overall P Overall OR
(95% CI)
Stage A P Stage A OR
(95% CI)
Stage B P Stage B OR
(95% CI)
Variant type Nearest gene
(distance)
Regulatory function from
ENCODE (±25 Kb)*
TCF3, BHLHE40, EP300,
E2F6, FOXP2, GABPA,
ZNF143, SPI1, USF1, EGR1,
E2F4, E2F1, MAFK, TCF7L2,
POU2F2, TAF1, PHF8, IRF1,
FOXA1 (±1 Kb)
rs517875
(3:174350886)
C/A (0.42) 5.56 × 10−4 1.09 (1.03–1.16) 0.35 1.01 (0.93–1.09) 1.06 × 10−7 1.23 (1.13–1.33) Intronic SNP NAALADL2 (0bp) (1) Near TFB sites for MAFK,
ESR1
rs7041895
(9:22162794)
A/C (0.43) 4.81 × 10−4 1.12 (1.05–1.18) 0.60 1.02 (0.95–1.10) 1.06 × 10−7 1.26 (1.16–1.37) Intergenic SNP CDKN2BAS1
(41 701bp)
Near histone modiﬁcation
mark H3K4Me1
rs1250258
(2:216300185)
C/T (0.27) 2.48 × 10−5 0.89 (0.83–0.95) 0.22 0.98 (0.90–1.07) 3.48 × 10−8 0.81 (0.74–0.88) Intronic SNP FN1 (0bp) (1) In histone modiﬁcation
mark H3K4Me3, H3K27Ac.
(2) In/near TFB sites for
POLR2A, TEAD4, TAF1,
MBD4, MXI1, RBBP5,
SIN3A, FOXA2, MAX,
EZH2, RCOR1, MYC
12:95403979
(12:95403979)
C/CT (0.11) 3.35 × 10−6 1.24 (1.13–1.36) 0.13 1.11 (0.98–1.24) 2.43 × 10−7 1.38 (1.23–1.56) Intergenic SNP NR2C1 (12 026bp) (1) Near TFB sites for
TRIM28, CBX3, USF1, CTCF
rs71415016
(14:96443958)
T/C (0.08) 1.16 × 10−4 1.19 (1.06–1.32) 0.16 1.03 (0.89–1.19) 3.00 × 10−7 1.38 (1.20–1.59) Intergenic SNP C14orf132
(61 880bp)
Near histone modiﬁcation
mark H3K4Me1
rs62469231
(7:114031174)
G/A (0.02) 1.10 × 10−5 1.44 (1.18–1.77) 0.018 1.23 (0.94–1.60) 4.95 × 10−7 1.77 (1.37–2.27) Intronic SNP FOXP2 (0bp) Near histone modiﬁcation
mark H3K4Me1
rs3920498
(1:22492887)
G/C (0.20) 1.10 × 10−5 1.19 (1.11–1.28) 0.034 1.11 (1.02–1.22) 6.49 × 10−7 1.30 (1.18–1.43) Intergenic SNP WNT4 (22 502bp) (1) In histone modiﬁcation
mark H3K4Me1, (2) In/near
TFB sites for RELA, pouf2f2,
ebf1 (±1 Kb).
rs6908034
(6:19773930)
G/A (0.16) 0.012 1.13 (1.02–1.25) 7.31 × 10−7 1.30 (1.17–1.45) Intronic SNP ID4 (64 056bp) Located in an anti-sense
RNA, RP1-167F1.2
rs12455952
(18:58840518)
T/G (0.19) 1.75 × 10−5 1.16 (1.07–1.25) 0.021 1.09 (0.99–1.20) 9.59 × 10−7 1.27 (1.15–1.40) Intergenic SNP CDH20
(317 287bp)
Near TFB sites for MAFK,
E2F4, FOS
rs138913144
(9:133897939)
A/ATATT (0.07) 4.47 × 10−3 0.86 (0.74–1.00) 9.94 × 10−7 0.68 (0.57–0.81) Intronic
insertion
LAMC3 (0bp) (1) Near a small nucleolar
RNA, SNORA31 (1246bp),
(2) Near histone
modiﬁcation mark H3K4Me1
TFB sites, transcription factor binding sites; rsid, SNP ID; Chr, chromosome; MAF, minor allele frequency; P, Association test P-value, OR, odds ratio; SNP, single-nucleotide polymorphism; GWAS, genome-wide association study.
*Histone modiﬁcation marks as identiﬁed from seven cell lines (GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK, NHLF) from ENCODE database and DNAse I hypersensitivity peaks identiﬁed from 95 cell types from ENCODE database
using UCSC genome browser annotation tools.
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enriched for association with endometriosis (P < 0.05) in this pathway
were (i) FN1 (ﬁbronectin 1, P = 9.75 × 10−4); (ii) FGA (ﬁbrinogen alpha
chain, P = 1.95 × 10−3); (iii) FGB (ﬁbrinogen beta chain; P = 3.95 × 10−3);
(iv) FGG (ﬁbrinogen gamma chain; P = 1.95 × 10−3); (v) RAP1B (Ras-
related protein Rap-1b; P = 9.67 × 10−3) and (vi) SOS1 (Son of
sevenless homolog 1; P = 7.50 × 10−4). The second MAPK-related
pathway signiﬁcantly enriched for association with all endometriosis
(P = 6.0 × 10−4, FDR-P = 0.029; Table II) was P130Cas linkage to
MAPK signaling for integrins, a Reactome pathway also including 15
genes. This pathway signiﬁes the role of p130Cas in survival signals
and cell motility from the extracellular matrix (ECM) through integrin,
activating the ERK1 ERK2 MAPK pathway. The two MAPK-related
pathways deﬁne similar functions as they overlap by 12 genes (Fig. 2).
Indeed, the top endometriosis-associated genes—shared by both
pathways—were FN1, FGA, FGB, FGG and RAP1B.
For Stage A endometriosis, the top pathway enriched in the
GWAS results was the ERK1 ERK2 MAPK pathway from the Signal
Transduction (ST) database (P = 5.0 × 10−4, FDR-P = 5.0 × 10−4,
Bonferroni-P = 0.011). The top associated genes in this pathway were
TRAF3 (TNF Receptor-Associated factor 3; P = 2.1 × 10−4); MAP2K1
(Mitogen-Activated Protein Kinase Kinase 1; P = 5.7 × 10−3); SOS1;
(P = 0.019); SHC1 (Src Homology two Domain Containing
Transforming Protein 1; P = 0.027); CREB5 (CAMP Responsive
Element Binding Protein 5; P = 0.022); NFKB1 (Nuclear factor of
Kappa Light Polypeptide Gene Enhancer in B-cells 1; P = 0.025); and
BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase; P = 0.032).
The ERK1 ERK2 MAPK pathway overlaps with p130Cas linkage to MAPK
signaling for integrins pathway by two genes: GRB2 and SOS1 (Fig. 2).
The MAP3K4 gene, in which we had observed SNP rs144240142 to
be associated with Stage A endometriosis, is part of two pathways
arising from the ST database: the p38 MAPK pathway and the c-Jun
amino-terminal protein kinase (JNK) MAPK pathway. The p38 MAPK
pathway overlaps with the ERK1 ERK2 MAPK pathway by 10 genes
(ATF1, CREB1, CREB3, CREB5, EEF2K, EIF4E, MAPK1, MKNK1,
MKNK2, NFKB1), while the JNK MAPK pathway overlaps by two genes
(DUSP4, SHC1) (Fig. 2).
Other pathways signiﬁcantly enriched (FDR-P and Bonferroni-
P < 0.05) in GWAS results for Stage A endometriosis were (Table II)
TRKA receptor (SA) and PIP3 signaling in cardiac myocytes (SIG). G
alpha S pathway (ST), Phosphoinositide three kinase pathway (ST),
Differentiation pathway in PC12 cells (ST), B cell receptor complexes (SA),
Insulin receptor pathway in cardiac myocytes (SIG) and PTEN pathway
(SA) were signiﬁcant at FDR < 0.05 but not after stringent Bonferroni
correction (see Materials and Methods).
For Stage B analysis, two pathways were signiﬁcantly enriched
(FDR-P and Bonferroni-P < 0.05): ECM glycoproteins (P = 1.8 × 10−3,
FDR-P = 7.1 × 10−3, Bonferroni-P = 0.018) including 196 genes
deﬁned by Matrisome Project gene sets (http://web.mit.edu/
hyneslab/matrisome/) (Naba et al., 2012), and Core matrisome com-
prising 275 genes encoding all known ECM glycoproteins, collagens
and proteoglycans (P = 1.4 × 10−3, FDR-P = 0.013, Bonferroni-
P = 0.014). The ECM glycoproteins gene set is a subset of the Core
Matrisome and thus many of the genes enriched in the endometriosis
GWAS overlap. Notably, this includes FN1, FGG and FGA, which are
also part of the Reactome MAPK-related pathways associated with all
endometriosis (Fig. 2).
Lastly, we set out to investigate to what extent pathways investi-
gated previously in hypothesis-based candidate gene studies were
highlighted by the hypothesis-free GWAS analyses. Among the 122
candidate genes investigated previously (see Materials and Methods),
there was signiﬁcant over-representation of investigation of 16 path-
ways (Table III), the top three being: Interleukin signaling pathway
(P = 2.3 × 10−12), Apoptosis signaling pathway (P = 9.7 × 10−9) and
Gonadotropin releasing hormone receptor pathway (P = 1.2 × 10−6).
Others covered inﬂammation-related pathways, cellular homeostatic
signaling, thrombolysis, angiogenesis and steroid biosynthesis. Only
2/122 genes were part of a pathway that was highlighted by our
GWAS pathway analysis: NFKB1 in ERK1 ERK2 MAPK pathway and
CDKN1B in PIP3 signaling in cardiac myocytes (Table III). The results
showed that of the pathways enriched in GWAS analyses only Insulin/
IGF pathway with MAPK cascade and PI3 kinase pathway featured in the
pathways explored in hypothesis-driven candidate gene association
studies conducted to date, but others did not.
Discussion
We have presented the ﬁrst comprehensive analysis investigating bio-
logical pathways underlying endometriosis pathogenesis using genome-
wide methodology. This analysis was based on GWAS results from all
endometriosis cases, Stage A and Stage B cases vs. controls. Because
the pathway results are based on genetic data, they provide strong evi-
dence of causal involvement of these pathways in disease development
and/or maintenance. In addition, we presented the ﬁrst GWAS ana-
lysis for Stage A disease, further exploring the hypothesis of distinct
causal pathophysiology on endometriosis subtypes.
The results conﬁrm earlier reports that Stage A vs. Stage B have
distinct genetic contributors (Painter et al., 2011; Nyholt et al., 2012;
Figure 1 Manhattan plot of association of single-nucleotide poly-
morphisms (SNPs) with Stage A endometriosis in the GWAS. Red
horizontal line marks the genome-wide signiﬁcance (P < 5 × 10−8),
and blue line marks nominal signiﬁcance (P < 5 × 10−6).
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Rahmioglu et al., 2014), and highlight for the ﬁrst time the role of
MAPK signaling in its pathogenesis. The GWAS analysis of Stage A dis-
ease resulted in a novel associated variant, rs144240142, in an intronic
region of MAP3K4, a gene that was also differentially expressed in
endometrium from endometriosis cases and controls in our analysis of
an independent data set (Tamaresis et al., 2014). This result is intri-
guing though it requires genotyping and replication in an independent
data set. MAP3K4 encodes for the protein MAPKKK4, which is part
of the p38 and JNK MAPK pathways. Subsequent pathway analysis
revealed ERK1 ERK2 MAPK as the most signiﬁcant pathway associated
with Stage A endometriosis.
The pathway analysis for all cases of endometriosis revealed two
pathways that were also linked to MAPK signaling: Grb2-Sos provides
linkage to MAPK signaling for Integrins and p130Cas linkage to MAPK sig-
naling for integrins. These pathways largely overlap (12 out of the 15
genes in each are the same), and reﬂect different routes through which
integrins (adhesion molecules) can activate ERK1 ERK2 MAPK signaling.
Wnt signaling was also implicated in all endometriosis, in line with
.............................................................................................................................................................................................
Table II Genome-wide pathway analysis of all, Stage A and Stage B endometriosis results identiﬁed in MAGENTA.
Database
(#pathways)
Pathway Geneset
size
P-value FDR P-
value
Bonferroni
P-value*
Expected
N genes
ObservedN genes
Overall endometriosis
REACTOME (671) Grb2-Sos
provides linkage
to MAPK
signaling for
integrins
15 2.8 × 10−5 3 × 10−3 NA 1 6 (FN1, FGG, FGA, FGB, RAP1B, SOS1)
SA (9) Wnt signaling 89 0.026 0.026 0.24 4 9 (WNT4, CTNNBIP1, RHOU, PPP2R1A, CTBP2,
HPRT1, CXXC4, SFRP1, KREMEN1)
REACTOME (671) p130CAS linkage
to MAPK
signaling for
integrins
15 6 × 10−4 0.029 NA 1 5 (FN1, FGG, FGA, FGB, RAP1B)
Stage A endometriosis
ST (23) ERK1 ERK2
MAPK pathway
32 5 × 10−4 5 × 10−4 0.011 2 7 (TRAF3, MAP2K1, SOS1, CREB5, NFKB1, SHC1,
BRAF)
SA (9) TRKA receptor 17 1 × 10−3 2.5 × 10−3 9.0 × 10−3 1 5 (ELK1, MAP2K1, SOS1, NTRK1, SHC1)
SIG (8) PIP3 signaling in
cardiac myocytes
67 1.6 × 10−3 4.5 × 10−3 0.013 3 10 (RPS6KB1, PTK2, YWHAG, PAK7, SOS1, CREB5,
SHC1, CDKN1B, IGFBP1, GSK3B)
ST (23) G alpha S
pathway
16 5.5 × 10−3 8.8 × 10−3 0.13 1 4 (RASGRF2, CREB5, BRAF, SNX13)
ST (23) Phosphoinositide
three kinase
pathway
37 9.1 × 10−3 9.1 × 10−3 0.21 2 6 (RPS6KB1, YWHAG, SOS1, SHC1, IGFBP1,
GSK3B)
ST (23) Differentiation
pathway in PC12
cells
45 5.5 × 10−3 0.019 0.13 2 7 (CREBBP, ELK1, RASGRF2, CREB5, NTRK1, SHC1,
BRAF)
SA (9) B cell receptor
complexes
24 0.026 0.026 0.24 1 4 (ELK1, MAP2K1, SOS1, SHC1)
SIG (8) Insulin receptor
pathway in
cardiac myocytes
51 0.033 0.033 0.26 2 6 (RPS6KB1, YWHAG, SOS1, SHC1, IGFBP1,
GSK3B)
SA (9) PTEN pathway 17 0.051 0.042 0.46 1 3 (SOS1, IPCEF1, SHC1)
Stage B endometriosis
NABA (10) ECM
glycoproteins
196 1.8 × 10−3 7.1 × 10−3 0.018 9 19 (FN1, LAMC3, THBS1, TNFAIP6, RSPO3, FBLN2,
SPARC, VWF, GLDN, LAMB3, MXRA5, FGG, FGA,
EMILIN2, TSPEAR, ZPLD1, EDIL3, WISP3, IGFBP6)
NABA (10) CORE
Matrisome
275 1.4 × 10−3 0.013 0.014 13 24 (FN1, LAMC3, THBS1, HSPG2, TNFAIP6, RSPO3,
FBLN2, SPARC, SPOCK3, VWF, COL12A1, GLDN,
LAMB3, MXRA5, DCN, LUM, FGG, FGA, EMILIN2,
TSPEAR, ZPLD1, HAPLN4, KERA, EDIL3)
*For databases with <25 pathways, we computed the Bonferroni P-value adjusted for the number of pathways within the given database resource, in addition to the FDR multiple-
testing correction computed by the MAGENTA software (see Materials and Methods). Note that the Bonferroni adjustment is likely to be conservative given that the pathways within
a resource are never fully independent of each other. Databases; SigmaAldrich (SA), Signaling Gateway (SIG), Signaling Transduction KE (ST), Matrisome Project gene sets (http://
web.mit.edu/hyneslab/matrisome/) (Naba et al., 2012) (NABA).
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previous reports of both single-SNP and pathway associations involv-
ing Wnt pathway genes (Painter et al., 2011; Nyholt et al., 2012;
Sanchez et al., 2014; Rahmioglu et al., 2015a, 2015b), although the
association was non-signiﬁcant after stringent Bonferroni multiple-
testing correction.
MAPKs comprise a kinase enzyme family that add phosphate groups
to other proteins to activate, triggering a cascade of downstream sig-
naling reactions that are involved in many physiological processes, such
as gene expression, mitosis, cell movement, metabolism, cell survival
and apoptosis. The protein kinase cascade consists of enzyme compo-
nents; MAPK kinase kinase (MAPKKK), MAPK kinase (MAPKK) and
MAP kinase (MAPK), that are activated consecutively (Fig. 3).
Extracellular stimuli activate the Grb2-Sos complex, which then pro-
motes Ras protein activation and which in turn activate the cytosolic
MAPK pathway that ﬁnally leads to intranuclear events and cellular
responses. Three main MAPK classes are distinguished by their bio-
logical function: ERKs acting in the control of cell division; JNKs regulat-
ing transcription; and p38 MAPK playing important roles in immune
response, cell survival and differentiation regulation. They are mostly
activated by inﬂammatory cytokines and environmental stresses, while
other stimuli include growth factors, neurotransmitters, steroid
hormones, osmolarity and cell adherence (Widmann et al., 1999;
Johnson and Lapadat, 2002).
A role for MAPK pathways has been recognized in a wide range of
diseases, including cancers (Lei et al., 2014), obesity-associated insulin
resistance (Hirosumi et al., 2002), ischemic heart disease (Bogoyevitch
et al., 2004) and autoimmune diseases (Genovese, 2009). In endomet-
riosis, MAPK signaling has been implicated previously, based on
observed differential expression proﬁles and induction of cell prolifer-
ation in ectopic vs. eutopic endometrial cells in women with endomet-
riosis vs. controls (Yotova et al., 2011; Li et al., 2013; Wu, et al.,
2014). Gene expression within the ERK MAPK pathway has been sug-
gested to be dysregulated in eutopic endometrium after experimental
endometriosis induction in a baboon model (Afshar et al., 2013).
However, these studies were unable to indicate whether these pro-
cesses were causative to, or resulting from, the disease. Our results
show that the association between MAPK signaling and endometriosis
has a genetic basis and therefore likely reﬂects a causal mechanism,
and furthermore, suggest that this association is limited to Stage A
disease.
An intriguing mechanism through which MAPK signaling could be
associated with Stage A endometriosis is through a role in increased
GRB2
SOS1/SOS1
BCAR1
CRK
Overall Endometriosis
p130Cas LINKAGE TO
MAPK SIGNALIN FOR INTEGRINS
(Reactome)
Overall Endometriosis
Grb2 Sos PROVIDES LINKAGE TO
MAPK SIGNALING FOR INTERGRINS
(Reactome)
APBB1IP PTK2
FGA* RAP1A
FGB RAP1B
FGG* SRC
FN1* TLN1
ITGA2B VWF
ITGB3
Stage A Endometriosis
ERK1 ERK2 MAPK PATHWAY
(ST)
ARAF
BAD
BRAF
DUSP6
DUSP9
KAT5
KLF6
MAPK3
MAP2K1
MAP2K2
MAP3K8
MOS
ATF1
CREB1
CREB3
CREB5
EEF2K
EIF4E
MAPK1
MKNK1
MKNK2
NFKB1
DUSP4
SHC1
ATF2
DLD
DUSP8
GAB1
GCK
JUN
MAP2K5
MAP2K7
MAP3K1
MAP3K11
MAP3K12
MAP3K13
MAP3K2
MAP3K3
MAP3K9
MAPK10
MAPK7
MAPK8
MAPK9
NFATC3
PAPPA
TP53
ZAK
DUSP1 MAPK12
ELK1 MAPK13
HSPB1 MAPK14
MAP2K3 MAPKAPK2
MAP2K6 MAPKAPK5
MAPK11 SRF
RAP1A
RPS6KA1
RPS6KA2
RPS6KA3
SOS2
TRAF3
IL1R1
AKT1 MAP2K4 NR2C2
CDC42 MAP3K10 TAB1
DUSP10 MAP3K4 TAB2
GADD45A MAP3K5 TRAF6
MAP3K7
MYEF2
p38 MAPK PATHWAY
(ST)
JNK MAPK PATHWAY
(ST)
Figure 2 Mitogen-activated protein kinase (MAPK)-related pathways enriched for genome-wide association study (GWAS) associations with endo-
metriosis. Genes for which association contributing most to the enrichment (P < 0.05) are highlighted in bold. *Genes taking part in ECM glycoproteins
and CORE matrisome pathways (NABA).
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sensitivity to pain, asMAPK pathways are differentially activated in neu-
rons and glia in inﬂammatory pain and neuropathic pain conditions
(Ji et al., 2009). A proportion of women with endometriosis have a
neuropathic component involved in their pain mechanism (Whitaker
et al., 2016). Interestingly, an animal model of endometriosis has
shown p38 MAPK activation to play a role in this mechanism (Chen
et al., 2015). Chronic pain patients appear less able to engage nocicep-
tive pain processing and to produce endogenous pain inhibition
(Tracey and Mantyh, 2007) and recent work suggests that dysfunction
within this system may predispose an individual to develop chronic
pain after an acute insult (De Felice et al., 2011). Thus, it may be that
MAPK signaling is not associated with the presence of endometriosis
per se, but with the experience of pain in women with Stage A disease,
thereby increasing the likelihood of investigation and thus diagnosis.
Our results show that associated variant rs144240142 resides in
MAP3K4, part of the JNK and p38 MAPK classes, which overlap with
the ERK1 ERK2 MAPK pathway that is genetically associated with Stage
A disease. The implicated MAPK pathways act on the MAP kinase
component level, more downstream in the cascade, close to the cell
nucleus (Fig. 3). As these MAPK classes are functionally connected,
they require a comprehensive functional investigation in relation to
endometriosis.
The most signiﬁcant pathways associated with Stage B (rAFS III/IV)
disease were related to ECM and adhesion processes: the Core
Matrisome, a large pathway containing 275 genes encoding all known
ECM glycoproteins, collagens and proteoglycans that includes a sub-
pathway, ECM glycoproteins containing 196 genes. Notably, the top
genes associated with Stage B endometriosis in these pathways include
FN1, FGG and FGA which are also part of the Reactome integrin linkage
to MAPK pathways associated with all endometriosis. These pathways
act on the MAPKKK component level, upstream in the cascade close
to cellular membrane (Fig. 3). GWAS and replication analyses have
shown that the association between genetic variants in FN1, encoding
for ﬁbronectin, and endometriosis is limited to Stage B disease
(Pagliardini et al., 2013; Rahmioglu et al., 2014). Our pathway results
.............................................................................................................................................................................................
Table III Most frequently investigated biological pathways for endometriosis through candidate gene studies, as deﬁned
by PANTHER database (July 2014)
PANTHER: Biological pathway Candidate genesa
Interleukin signaling pathway (n = 95) 13 (P = 2.3 × 10−12)
Apoptosis signaling pathway (n = 113) 11 (P = 9.7 × 10−9)
Gonadotropin releasing hormone receptor pathway (n = 228) 12 (P = 1.2 × 10−6)
Inﬂammation mediated by chemokine/cytokine signaling (n = 233) 12 (P = 1.6 × 10−6)
p53 pathway (n = 81) 8 (P = 3.9 × 10−6)
Plasminogen activating cascade (n = 17) 5 (P = 9.4 × 10−6)
Insulin/IGF pathway-protein kinase B signaling cascade (n = 37) 6 (P = 1.4 × 10−5)
p53 pathway feedback loops 2 (n = 47) 5 (P = 1.3 × 10−3)
VEGF signaling pathway (n = 58) 5 (P = 3.6 × 10−3)
Angiogenesis (n = 152) 7 (P = 4.5 × 10−3)
Androgen/estrogene/progesterone biosynthesis (n = 10) 3 (P = 4.7 × 10−3)
Insulin/IGF pathway-mitogen-activated protein kinase kinase/MAP kinase cascade (n = 32) 4 (P = 6.1 × 10−3)
Alzheimer disease-presenilin pathway (n = 109) 6 (P = 6.5 × 10−3)
EGF receptor signaling pathway (n = 123) 6 (P = 0.013)
PI3 kinase pathway (n = 47) 4 (P = 0.027)
aOut of the 122 candidate genes 65 do not participate in any of the PANTHER pathways.
Figure 3 MAPK cascade and pathway components in mammalian
cells. Adapted from Cabodi et al. (2010) and Zhang and Liu (2002).
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conﬁrm a key role of ECM glycoprotein biology limited to Stage B dis-
ease. This observation is interesting, because it is the pathological
accumulation of ECM proteins that deﬁnes ﬁbrosis—a common hall-
mark in Stage B (rAFS III/IV) disease.
The role of integrins and the ECM in endometriosis has long been
postulated (Klemmt et al., 2007; Pitsos and Kanakas, 2009). Integrins
are transmembrane adhesion receptors and construct bridges for cell–
cell and cell–ECM interactions. Studies have shown that integrin
expression, particularly on peritoneal mesothelial cells, indicates a
potential attachment site for ectopic endometrial cells (Witz et al.,
2000), while integrins present in endometriosis lesions have been
shown to be of peritoneal origin (Hull et al., 2008). Aberrations in
ECM have been documented in relation to endometriosis, but it is not
clear whether the mesothelial layer is damaged thus exposing the
ECM, or whether inherent changes in the ECM promote the adher-
ence of primary endometrial cells. Our ﬁndings suggest the latter.
GWAS analysis is a powerful tool in uncovering associations
between common genetic variants and complex diseases such as en-
dometriosis (Manolio et al., 2009), but requires large sample sizes to
enable detection of associated variants at ‘genome-wide signiﬁcance’
(P < 5 × 10−8). For instance, for breast cancer the largest GWAS
meta-analysis has included >55 000 cases to date, ﬁnding 67 GWAS
variants together explaining 14% of heritability (Michailidou et al.,
2013). Case numbers for endometriosis discovery GWAS have been
<1/10 the size, and have discovered only eight variants that explain
<4% of heritability (Rahmioglu et al., 2014). Pathway analysis provides
a powerful approach to leverage GWAS variant data in their cumula-
tive effects into genes and pathways, thus substantially reducing the
statistical impact of multiple testing and superseding the agnostic
approach by highlighting functional pathways involved in pathogenesis.
Increased sample sizes for endometriosis GWAS analysis are needed
to identify further genetic variants associated with disease pathology
that will also add to the analysis power and robustness of the pathways
identiﬁed for endometriosis.
Drawbacks of pathway analysis are (i) only variants in or near genes
are assigned to genes so that a large proportion of GWAS evidence
pertaining to intergenic variants is disregarded; (ii) reliance on the con-
tents of pathway databases and on the available software tools within
them. Better studied biological processes are more likely to be deﬁned
into (more detailed) pathways than less well-studied ones. In our ana-
lysis, this may have resulted in the relatively greater detail of the differ-
ent MAPK pathways highlighted. Our results summarizing candidate
gene studies conducted to date showed that these have largely
focused on pathways that do not feature in our genome-wide results.
This does not mean that these candidate-based pathways are irrele-
vant to endometriosis causation, but rather that more consideration
should be given to MAPK regulated ECM and integrin involving pro-
cesses and Wnt signaling as relatively under-investigated pathways, in
terms of biological follow-up.
An important method for understanding the effects of variants on
downstream molecular processes is their integration with transcrip-
tomic and epigenomic data. However, such functional studies need to
be conducted in disease-related tissues, such as endometrium for
endometriosis. There are no genome-wide data sets available cur-
rently that associate genetic variants with gene expression levels
(expression quantitative trait loci) in endometrium. Currently, none of
the large-scale genomic proﬁling initiatives such as GTex (Consortium,
2013) and the NIHR Epigenome Roadmap (Skipper et al., 2015)
include endometrium, and very limited endometrium annotation data
are available in ENCODE (Consortium, 2012). The lack of genomic
annotation data currently severely impedes the ‘translation’ of genetic
signals associated with endometriosis into their downstream effects.
MAPK, andWnt signaling, pathways have been targeted for drug dis-
covery, mainly in the area of cancer (Sebolt-Leopold and Herrera,
2004), but the ubiquitous functional nature of these pathways repre-
sents considerable challenges for a non-malignant condition such as
endometriosis. Protein kinase inhibitors targeting the ERK1 ERK2 path-
way were observed to control deep inﬁltrating endometriosis progres-
sion (Ngo et al., 2010) and their role in endometriosis treatment has
been explored in several studies (Santulli et al., 2015). To date, they
present unacceptable adverse effects, including ovulation inhibition
and teratogenicity, skin and gastrointestinal toxicities, weight loss,
fatigue, hypertension and infections (Krajewska et al., 2015). Targeting
the Wnt signaling pathway has similar challenges (Duchartre et al.,
2016). This does not negate the potential for more speciﬁc targets to
be identiﬁed in these pathways that limit unwanted consequences, or
topical rather than systemic applications to be developed. More stud-
ies are needed in this area.
Our results offer further support for the hypothesis of at least par-
tially distinct causal pathophysiology for minimal/mild (rAFS I/II) vs.
moderate/severe (rAFS III/IV) endometriosis. Based on our results,
we postulate that integrin-mediated MAPK activation plays a key cau-
sal role in the establishment of endometriotic lesions. Development of
Stage I/II disease is further characterized by involvement of the intra-
cellular ERK1 ERK2 pathway acting downstream in the MAP kinase
cascade, whereas Stage III/IV disease is characterized by other extra-
cellular processes leading to increased ﬁbrogenesis.
Supplementary data
Supplementary data are available at Human Reproduction online.
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